Annual financial results as of 31 December, 2018
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.
Update on the restructuring of the AB Science clinical development department in 2018
19/12/2018 – AB Science provides the main achievements of this restructuring.
Patients
The following studies are currently recruiting patients Masitinib in prostate cancer The following studies will start recruitment in 2019: Masitinib in Amyotrophic Lateral Sclerosis Masitinib in indolent systemic severe mastocytosis AB8939 in acute myeloid leukemia Patients If you wish to participate in this study, please contact us at the following address:clinical@ab-science.com
Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment
22/10/2018 – Final results will be available in 2019.
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.
First half of 2018 revenues
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.
Results of the Combined General Shareholders’ Meeting held on June 29 2018
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.